TScan Therapeutics, Inc. (TCRX) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TCRX Revenue Growth
Revenue Breakdown (FY 2025)
TCRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
TCRX Revenue Analysis (2019–2025)
As of May 8, 2026, TScan Therapeutics, Inc. (TCRX) generated trailing twelve-month (TTM) revenue of $8.2 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, TCRX's 5-year compound annual growth rate (CAGR) stands at +56.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $21.0 million in 2023.
Revenue diversification analysis shows TCRX's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including TCRT (+0.0% YoY), AGEN (+10.4% YoY), and KYMR (-12.6% YoY), TCRX has underperformed the peer group in terms of revenue growth. Compare TCRX vs TCRT →
TCRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TCRXCurrent | $8M | -100.0% | +56.9% | -1315.4% | |
 TCRT | $10,000 | +0.0% | - | -48120.0% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% |
TCRX Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $10.3M | +266.7% | $7.5M | 72.2% | $-135,813,000 | -1315.4% |
| 2024 | $2.8M | -86.6% | $2.8M | 100.0% | $-134,821,000 | -4787.7% |
| 2023 | $21.0M | +55.5% | $21.0M | 100.0% | $-93,458,000 | -444.0% |
| 2022 | $13.5M | +33.5% | $13.5M | 100.0% | $-66,636,000 | -492.3% |
| 2021 | $10.1M | +834.7% | $10.1M | 100.0% | $-48,641,000 | -479.6% |
| 2020 | $1.1M | - | $-19,492,000 | -1796.5% | $-26,233,000 | -2417.8% |
| 2019 | $0 | - | $-9,442,000 | - | $-14,210,000 | - |
See TCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TCRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTCRX — Frequently Asked Questions
Quick answers to the most common questions about buying TCRX stock.
Is TCRX's revenue growth accelerating or slowing?
TCRX revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +56.9%. TTM revenue fell to $8M. This reverses the prior growth trend.
What is TCRX's long-term revenue growth rate?
TScan Therapeutics, Inc.'s 5-year revenue CAGR of +56.9% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is TCRX's revenue distributed by segment?
TCRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.